Data integrity inspections that have disrupted pharmaceutical exports from India to the US and Europe are spreading to exporters in China and other countries, as well as to domestic US and European manufacturers that may be unprepared for them.
Even as FDA authorities warn global manufacturers against complacency, there are indications that they remain vulnerable to the type of...